TRDA Live signals | Maximize Profits with Getagraph.com

BUY 102102 min ago

@ $14.49

Issued: 13 Feb 2024 @ 09:30

Return: -11.04%

Previous signal: Feb 7 - 09:30

Previous signal: Sell

Return: 1.26 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases...

Stats
Today's Volume	42 822.00
Average Volume	77 048.00
Market Cap	433.12M
EPS	$0 ( 2024-03-18 )
Next earnings date	( $-0.380 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-64.45
ATR14	$0.0480 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Kim Peter S	Buy	2 600	Common Stock
2024-03-28	Kim Peter S	Buy	1 512	Common Stock
2024-03-26	Kim Peter S	Buy	2 750	Common Stock
2024-03-25	Kim Peter S	Buy	3 180	Common Stock
2024-03-22	Kim Peter S	Buy	3 118	Common Stock

INSIDER POWER
70.10
Last 99 transactions
Buy: 995 092 \| Sell: 209 386

Volume Correlation

Long: -0.24 (neutral)

Short: -0.79 (moderate negative)

Signal:(26.854) Neutral

Entrada Therapeutics, Correlation

10 Most Positive Correlations
GXGX	0.876
MTP	0.872
HOL	0.871
PEV	0.864
IMGN	0.861
EPSN	0.85
PLIN	0.847
THCB	0.842
LGMK	0.839
MTSL	0.839

10 Most Negative Correlations
RAVN	-0.874
CSPI	-0.853
NECB	-0.85
CREC	-0.848
TBSAU	-0.848
GHIX	-0.846
HOFT	-0.842
ENTF	-0.842
FICV	-0.842
IVAC	-0.839

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Entrada Therapeutics, Correlation - Currency/Commodity

0.19
( neutral )

0.29
( neutral )

0.00
( neutral )

0.45
( neutral )

0.52
( weak )

0.53
( weak )

Entrada Therapeutics, Financials

Annual	2023
Revenue:	$129.01M
Gross Profit:	$126.17M (97.80 %)
EPS:	$-0.200

Q4	2023
Revenue:	$41.85M
Gross Profit:	$41.11M (98.24 %)
EPS:	$-0.290

Q3	2023
Revenue:	$43.74M
Gross Profit:	$42.94M (98.17 %)
EPS:	$1.070

Q2	2023
Revenue:	$18.17M
Gross Profit:	$17.47M (96.15 %)
EPS:	$-0.780

Financial Reports:

No articles found.

Entrada Therapeutics,

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.